WallStreetZenWallStreetZen

NASDAQ: RCKT
Rocket Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RCKT

Based on 6 analysts offering 12 month price targets for Rocket Pharmaceuticals Inc

Min Forecast
$3.00-37.5%
Avg Forecast
$50.33+948.6%
Max Forecast
$263.00+5,379.17%

Should I buy or sell RCKT stock?

Based on 6 analysts offering ratings for Rocket Pharmaceuticals Inc.

Hold
Strong Buy
3 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
2 analysts 33.33%
Although RCKT's forecast from analysts indicates a "Hold", our proven Zen Rating quant model rates RCKT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their RCKT stock forecasts and price targets.

RCKT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-02
lockedlocked$00.00+00.00%2026-02-27
lockedlocked$00.00+00.00%2025-11-18
lockedlocked$00.00+00.00%2025-11-18
lockedlocked$00.00+00.00%2025-10-14
Leerink Partners
Bottom 2%
2
HoldMaintains$7.00+45.83%2025-10-03

1 of 1

Forecast return on equity

Is RCKT forecast to generate an efficient return?

Company
-21.17%
Industry
206.77%
Market
229.52%
RCKT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RCKT forecast to generate an efficient return on assets?

Company
-17.76%
Industry
94.16%
RCKT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RCKT earnings per share forecast

What is RCKT's earnings per share in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
-$1.55
Avg 2 year Forecast
-$1.25
Avg 3 year Forecast
-$0.93

RCKT revenue forecast

What is RCKT's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$18.4M
Avg 2 year Forecast
$36.3M
Avg 3 year Forecast
$84.0M

RCKT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RCKT$4.80$50.33+948.60%Hold
FULC$7.87$17.83+126.59%Buy
LXEO$7.07$20.17+185.25%Strong Buy
NMRA$3.06$8.00+161.44%Buy
PRTA$9.36$24.25+159.08%Buy
View Top Biotech Stocks

Rocket Pharmaceuticals Stock Forecast FAQ

Is Rocket Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: RCKT) stock is to Hold RCKT stock.

Out of 6 analysts, 3 (50%) are recommending RCKT as a Strong Buy, 0 (0%) are recommending RCKT as a Buy, 1 (16.67%) are recommending RCKT as a Hold, 0 (0%) are recommending RCKT as a Sell, and 2 (33.33%) are recommending RCKT as a Strong Sell.

If you're new to stock investing, here's how to buy Rocket Pharmaceuticals stock.

What is RCKT's earnings growth forecast for 2026-2028?

(NASDAQ: RCKT) Rocket Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 41.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 38.38%.

Rocket Pharmaceuticals's earnings in 2026 is -$223,123,000.On average, 17 Wall Street analysts forecast RCKT's earnings for 2026 to be -$168,531,881, with the lowest RCKT earnings forecast at -$194,707,901, and the highest RCKT earnings forecast at -$115,137,576. On average, 14 Wall Street analysts forecast RCKT's earnings for 2027 to be -$135,548,575, with the lowest RCKT earnings forecast at -$213,859,498, and the highest RCKT earnings forecast at -$84,358,224.

In 2028, RCKT is forecast to generate -$101,436,150 in earnings, with the lowest earnings forecast at -$181,940,170 and the highest earnings forecast at $79,798,320.

What is RCKT's revenue growth forecast for 2026-2028?

(NASDAQ: RCKT) Rocket Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 21.94%.

Rocket Pharmaceuticals's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast RCKT's revenue for 2026 to be $1,994,198,019, with the lowest RCKT revenue forecast at $0, and the highest RCKT revenue forecast at $16,302,742,513. On average, 14 Wall Street analysts forecast RCKT's revenue for 2027 to be $3,942,037,013, with the lowest RCKT revenue forecast at $0, and the highest RCKT revenue forecast at $14,819,688,020.

In 2028, RCKT is forecast to generate $9,118,505,182 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $46,169,028,061.

What is RCKT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RCKT) forecast ROA is -17.76%, which is lower than the forecast US Biotechnology industry average of 94.16%.

What is RCKT's Price Target?

According to 6 Wall Street analysts that have issued a 1 year RCKT price target, the average RCKT price target is $50.33, with the highest RCKT stock price forecast at $263.00 and the lowest RCKT stock price forecast at $3.00.

On average, Wall Street analysts predict that Rocket Pharmaceuticals's share price could reach $50.33 by Mar 2, 2027. The average Rocket Pharmaceuticals stock price prediction forecasts a potential upside of 948.6% from the current RCKT share price of $4.80.

What is RCKT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RCKT) Rocket Pharmaceuticals's current Earnings Per Share (EPS) is -$2.01. On average, analysts forecast that RCKT's EPS will be -$1.55 for 2026, with the lowest EPS forecast at -$1.79, and the highest EPS forecast at -$1.06. On average, analysts forecast that RCKT's EPS will be -$1.25 for 2027, with the lowest EPS forecast at -$1.97, and the highest EPS forecast at -$0.78. In 2028, RCKT's EPS is forecast to hit -$0.93 (min: -$1.68, max: $0.74).

What is RCKT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RCKT) forecast ROE is -21.17%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.